花旗银行研究报告指，下调阿里健康(00241.HK) 2026及27财年收入预测3%及6%，每股盈利预测亦下调23%与19%，以反映收入增长放缓，及由于处方药销售增加所致的毛利率下滑。对其目标价由9.5元下调至8.5元，评级“买入”。报告提及，阿里健康2025年财年收入按年升13%至306亿元人民币，净利润升62%至14亿元人民币，经调整净利润升36%至19.5亿元人民币，符合最新指引。毛利率从...
Source Link花旗银行研究报告指，下调阿里健康(00241.HK) 2026及27财年收入预测3%及6%，每股盈利预测亦下调23%与19%，以反映收入增长放缓，及由于处方药销售增加所致的毛利率下滑。对其目标价由9.5元下调至8.5元，评级“买入”。报告提及，阿里健康2025年财年收入按年升13%至306亿元人民币，净利润升62%至14亿元人民币，经调整净利润升36%至19.5亿元人民币，符合最新指引。毛利率从...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.